A heavily pretreated patient with relapsed/refractory diffuse large B-cell lymphoma achieved complete remission within 28 days following a single dose of Genocury Biotech's novel in vivo CD19 CAR-T therapy.
Galapagos's lead CD19 CAR-T candidate GLPG5101 demonstrated compelling clinical results across three non-Hodgkin lymphoma indications, with complete response rates of 100% in MCL and 95% in MZL/FL.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.